AstraZeneca Access 360™ Enrollment Form



Please complete form, sign, and fax all pages to 1-833-329-2360. For questions or assistance, please call Access 360, Monday - Friday, 8 AM — 8 PM ET at 1-833-360-4357.

| | nacy Research and Triage (Acces Authorization Follow-up with <i>I</i> | · · | | | se note, this is not applicable to Buy & Bi It's prior authorization) |
|--|--|---|--|-------------------------------------|--|
| | ly complete if patient signs Patient Authoriz | •• | | | , |
| Addition | nal Services: | | | | |
| | & Billing Support | * * | (5) | | |
| lo enroll ii | n AZ&Me™ (Patient Assistance Pro | gram), visit www.azandmeap | op.com. (Eligibility rules apply.) | | |
| Patient Information | | | | | |
| First Name: | | _ Last Name: | | Patient DOB: | / Gender: 🗆 N |
| Street: | | City: | | State | e: ZIP: |
| | | | | | |
| | | | · | | |
| | | | - | | OK to contact patient? |
| OK to leave a detailed voicemai | il? ☐ Yes ☐ No Has the patien | nt received the Patient Welcome | e Kit? ☐ Yes ☐ No Communio | cation Preference (ch | oose one): Email Text Botl |
| Patient Authorization | | | FASENRA 360 Support | Program (Savings | Program and Additional Services |
| have read and agree to the Pati | ient Authorization included on Page | 2 | | | Patient Authorization included on Page |
| | 1 | | | | 1 1 |
| Patient Signature/Legal Represe | entative MM D | D YYYY | Patient Signature/Legal R | epresentative | MM DD YYYY |
| Printed Name/Relationship to Pa | atient (if applicable) | | Printed Name/Relationshi | tionship to Patient (if applicable) | |
| | Please include front and ba | | pharmacy cards or complete | this section. | |
| | ce Medicare/Medicaid/Tricare | ☐ No insurance | 1 | | Pharmacy Insurance |
| | ce Medicare/Medicaid/Tricare | | pharmacy cards or complete Secondary Medical Ins | | Pharmacy Insurance |
| ☐ Commercial/Private Insuranc | ce Medicare/Medicaid/Tricare | ☐ No insurance | 1 | | Pharmacy Insurance |
| Commercial/Private Insurance | e | ☐ No insurance | 1 | | Pharmacy Insurance |
| Commercial/Private Insurance Insurance Provider Insurance Phone # | e | ☐ No insurance | 1 | | Pharmacy Insurance |
| Insurance Provider Insurance Phone # Cardholder Name (if not the p | e | ☐ No insurance | 1 | | Pharmacy Insurance |
| Insurance Provider Insurance Phone # Cardholder Name (if not the p | e | ☐ No insurance | 1 | | Pharmacy Insurance |
| Insurance Provider Insurance Phone # Cardholder Name (if not the particular than the p | e | ☐ No insurance | 1 | | Pharmacy Insurance |
| Insurance Provider Insurance Phone # Cardholder Name (if not the particular policy # Group # BIN/PCN | e | No insurance ry Medical Insurance | Secondary Medical Ins | surance | • |
| Insurance Provider Insurance Provider Insurance Phone # Cardholder Name (if not the part of the part o | Prescriber Name: | No insurance ry Medical Insurance | Secondary Medical Ins | surance | Pharmacy Insurance Fax #: |
| Insurance Provider Insurance Provider Insurance Phone # Cardholder Name (if not the provider DOB Policy # Group # BIN/PCN Provider Information Practice Name: | Prescriber Name: | No insurance ry Medical Insurance X Phone #: | Secondary Medical Ins | surance | Fax #: |
| Insurance Provider Insurance Provider Insurance Phone # Cardholder Name (if not the part of the part o | Prescriber Name: | X Phone #: City: | X Specialty: | surance | |
| Insurance Provider Insurance Provider Insurance Phone # Cardholder Name (if not the part of the part o | Primal patient) Prescriber Name: | X Phone #: City: | Secondary Medical Ins X Specialty: | Office Staff Phone: _ | Fax #: ZIP: |
| Insurance Provider Insurance Provider Insurance Phone # Cardholder Name (if not the particular policy # Group # BIN/PCN Provider Information Practice Name: Street: Authorized HCP Office Staff Name | Prescriber Name: | X Phone #: City: | Secondary Medical Ins X Specialty: Authorized HCP Prescriber NPI #: | Office Staff Phone: _ | Fax #: ZIP: |

1



Patient Authorization

I authorize my health care providers (HCPs) and staff, my health plan, and my pharmacies to use and share Protected Health Information (my "Information") with AstraZeneca (including Access 360) and its affiliates, as well as its contractors ("AstraZeneca"). My Information includes my prescription-related health records, Information about my health care plan benefits, demographic, contact, and any other Information bearing on my health. My Information may be used to verify treatment and payment decisions with my HCPs; investigate and assist with coordination of coverage for AstraZeneca products; coordinate prescription fulfillment and financial assistance; and perform internal analysis at AstraZeneca to better meet patient needs. I understand and agree that AstraZeneca may contact me by mail, email, and telephone. I understand that federal privacy laws may not protect my Information once it is disclosed; however, AstraZeneca agrees to protect my Information by using and disclosing it only for purposes specified. I understand that I can refuse to sign this Authorization and that this will not affect my treatment or payment for treatment, insurance coverage, or eligibility for benefits. However, if I do not sign this Authorization, I will not be able to receive Access 360 support. I understand that I may cancel this Authorization at any time by calling 1-833-360-HELP or by mailing a letter requesting such cancellation to Access 360 at One MedImmune Way, Gaithersburg, MD 20878. I understand that any such cancellation will not apply to any Information already used or disclosed based on this Authorization prior to their receipt of the cancellation. This authorization expires two (2) years from the date signed on Page 1, unless a shorter period is required by state law.

FASENRA 360 Support Program

FASENRA Savings Program

The FASENRA Savings Program is designed to facilitate your access to FASENRA. By providing your authorization, you allow your health care providers, insurance companies and pharmacies to use and share your health care information with the FASENRA Savings Program so that you can participate in this savings program. Your health information may be seen by AstraZeneca and companies working on its behalf for this savings program.

Additional Services

I understand that I may also receive ongoing information and support related to my condition which includes, but is not limited to, providing me with educational and promotional materials, services related to my medical condition or therapy such as injection support for self-administration and for market research purposes which includes contacting me to participate in focus groups, surveys or interviews. This may include AstraZeneca or a third party working on AstraZeneca's behalf contacting me by telephone, email and/or text message regarding AstraZeneca support programs that may be of interest to me. My Information may also be used to perform internal analysis at AstraZeneca. Information provided by AstraZeneca does not take the place of talking to your health care provider about your treatment or condition.

I understand that I can refuse to sign this Authorization and that this will not affect my treatment or payment for treatment, insurance coverage, or eligibility for benefits. I understand that I may cancel this Authorization at any time by calling 1-833-360-HELP or by mailing a letter requesting such cancellation to Access 360 at One MedImmune Way, Gaithersburg, MD 20878.

I consent to receive marketing and non-marketing calls and texts from and on behalf of AstraZeneca and AstraZeneca's Access 360, made with an autodialer or prerecorded voice, at the phone number(s) provided. I understand that my consent is not required or a condition of purchase. Message and data rates may apply. Text STOP to opt out and HELP for help.

AstraZeneca or third parties working on its behalf will not sell or rent your personal information. Please visit www.globalprivacy.astrazeneca.com to review our Privacy Notice.

AstraZeneca Access 360™ Enrollment Form



| First Name: Patient Last | Name: | | Patient DOB: | | 1 |
|---|--|--|---|-----------------|-------|
| Clinical Information | | | | | |
| Diagnosis ☐ J45.50 Severe persistent asthma, uncomplicated | ☐ Other | | | | |
| ISD AAS I | Number of asthma exacerl | | | corticosteroio | ds ar |
| Eosinophil Count: cells/μL Date of Test:// | | | • | | |
| Acquisition Information | | | | | |
| Administration Method (choose one): Pre-Filled Syringe (Office-Admin | nistered) 🗆 Pen (Self-Administered) 🗀 Would | like to understand | coverage for both | administration | n met |
| ☐ In-network Specialty Pharmacy Provider (SPP)* (Preferred SPP: |) | | | | |
| *If you have questions about in-network SPP(s) for your patient, contact Access 360 at 1 | -833-360-4357. | | | | |
| $\hfill \square$ Buy & Bill (prescription information does not need to be completed, research Buy & Bill | only) | | | | |
| $\hfill\square$ I am unsure/undecided how I will obtain FASENRA (Access 360 will research both SPP are | nd Buy & Bill options) | | | | |
| Place of Administration (choose one): ☐ Prescribing Office (Pre-Filled Sy | ringe) 🔲 Patient Home (Pen) 🔲 Alternate Site | of Care (ASOC)† (P | re-Filled Syringe) | | |
| Alternate Site of Care (ASOC) Information ONLY complete this section | if the place of administration differs from the | prescribing offic | e. | | |
| Administering Practice/Facility: | | | | | |
| Phone #: Fax #: | - · | | | | |
| NPI #: Street: | | | | | |
| Medicare Provider # (PTAN): | | | | | |
| †An ASOC is a place of administration that differs from the prescribing office. Alternate sites of c | | | | | |
| | | | | | |
| Prescription Information | | | | | |
| Prescription Information Rx FASENRA® (benralizumab) | | | | | |
| | If primary choice is not covered, what is | s your secondary | choice? | | |
| Rx FASENRA® (benralizumab) | If primary choice is not covered, what is ☐ FASENRA® (benralizumab) 30 mg/m | • | | | |
| Rx FASENRA® (benralizumab) What is your primary choice? | ' ' | nL single-dose pref | | | |
| Rx FASENRA® (benralizumab) What is your primary choice? ☐ FASENRA® (benralizumab) 30 mg/mL single-dose prefilled syringe | ☐ FASENRA® (benralizumab) 30 mg/m Office-Administered (10-digit NDC: | nL single-dose pref 0310-1730-30) | illed syringe | | |
| Rx FASENRA® (benralizumab) What is your primary choice? ☐ FASENRA® (benralizumab) 30 mg/mL single-dose prefilled syringe Office-Administered (10-digit NDC: 0310-1730-30) | □ FASENRA® (benralizumab) 30 mg/m Office-Administered (10-digit NDC: □ FASENRA Pen™ (benralizumab) 30 m | nL single-dose pref 0310-1730-30) ng/mL single-dose | illed syringe | | |
| Rx FASENRA® (benralizumab) What is your primary choice? ☐ FASENRA® (benralizumab) 30 mg/mL single-dose prefilled syringe Office-Administered (10-digit NDC: 0310-1730-30) ☐ FASENRA Pen™ (benralizumab) 30 mg/mL single-dose autoinjector | ☐ FASENRA® (benralizumab) 30 mg/m Office-Administered (10-digit NDC: ☐ FASENRA Pen™ (benralizumab) 30 n Self-Administered (10-digit NDC: 03 | nL single-dose pref 0310-1730-30) ng/mL single-dose 810-1830-30) | illed syringe autoinjector | | |
| Rx FASENRA® (benralizumab) What is your primary choice? ☐ FASENRA® (benralizumab) 30 mg/mL single-dose prefilled syringe Office-Administered (10-digit NDC: 0310-1730-30) ☐ FASENRA Pen™ (benralizumab) 30 mg/mL single-dose autoinjector Self-Administered (10-digit NDC: 0310-1830-30) ☐ Please send alcohol wipe and sterile gauze to patient | ☐ FASENRA® (benralizumab) 30 mg/m Office-Administered (10-digit NDC: ☐ FASENRA Pen™ (benralizumab) 30 m Self-Administered (10-digit NDC: 03 | nL single-dose pref 0310-1730-30) ng/mL single-dose 310-1830-30) I wipe and sterile g | illed syringe autoinjector Jauze to patient | | |
| Rx FASENRA® (benralizumab) What is your primary choice? ☐ FASENRA® (benralizumab) 30 mg/mL single-dose prefilled syringe Office-Administered (10-digit NDC: 0310-1730-30) ☐ FASENRA Pen™ (benralizumab) 30 mg/mL single-dose autoinjector Self-Administered (10-digit NDC: 0310-1830-30) | ☐ FASENRA® (benralizumab) 30 mg/m Office-Administered (10-digit NDC: ☐ FASENRA Pen™ (benralizumab) 30 m Self-Administered (10-digit NDC: 03 ☐ Please send alcoho ☐ Optional: Free Limited | nL single-dose pref 0310-1730-30) ng/mL single-dose 310-1830-30) I wipe and sterile <u>c</u> | autoinjector jauze to patient Request | | |
| Rx FASENRA® (benralizumab) What is your primary choice? ☐ FASENRA® (benralizumab) 30 mg/mL single-dose prefilled syringe Office-Administered (10-digit NDC: 0310-1730-30) ☐ FASENRA Pen™ (benralizumab) 30 mg/mL single-dose autoinjector Self-Administered (10-digit NDC: 0310-1830-30) ☐ Please send alcohol wipe and sterile gauze to patient Has this patient started therapy? ☐ Yes ☐ No | □ FASENRA® (benralizumab) 30 mg/m Office-Administered (10-digit NDC: □ FASENRA Pen™ (benralizumab) 30 m Self-Administered (10-digit NDC: 03 □ Please send alcoho □ Optional: Free Limited Free Limited Supply is available for ea | nL single-dose pref 0310-1730-30) ng/mL single-dose 310-1830-30) I wipe and sterile <u>c</u> | autoinjector jauze to patient Request | proval by their | |
| Rx FASENRA® (benralizumab) What is your primary choice? ☐ FASENRA® (benralizumab) 30 mg/mL single-dose prefilled syringe Office-Administered (10-digit NDC: 0310-1730-30) ☐ FASENRA Pen™ (benralizumab) 30 mg/mL single-dose autoinjector Self-Administered (10-digit NDC: 0310-1830-30) ☐ Please send alcohol wipe and sterile gauze to patient Has this patient started therapy? ☐ Yes ☐ No If yes, how many doses has the patient received? ☐ Loading Dose 30 mg/mL solution in a single dose administered by | ☐ FASENRA® (benralizumab) 30 mg/m Office-Administered (10-digit NDC: ☐ FASENRA Pen™ (benralizumab) 30 m Self-Administered (10-digit NDC: 03 ☐ Please send alcoho ☐ Optional: Free Limited Free Limited Supply is available for en insurance company for FASENRA. | nL single-dose pref 0310-1730-30) ng/mL single-dose 310-1830-30) I wipe and sterile of Supply (FLS) ligible patients who | autoinjector jauze to patient Request | proval by their | |
| Rx FASENRA® (benralizumab) What is your primary choice? ☐ FASENRA® (benralizumab) 30 mg/mL single-dose prefilled syringe Office-Administered (10-digit NDC: 0310-1730-30) ☐ FASENRA Pen™ (benralizumab) 30 mg/mL single-dose autoinjector Self-Administered (10-digit NDC: 0310-1830-30) ☐ Please send alcohol wipe and sterile gauze to patient Has this patient started therapy? ☐ Yes ☐ No If yes, how many doses has the patient received? | □ FASENRA® (benralizumab) 30 mg/m Office-Administered (10-digit NDC: □ FASENRA Pen™ (benralizumab) 30 m Self-Administered (10-digit NDC: 03 □ Please send alcoho □ Optional: Free Limited Free Limited Supply is available for ea | nL single-dose pref 0310-1730-30) ng/mL single-dose 810-1830-30) I wipe and sterile of Supply (FLS) ligible patients who | autoinjector jauze to patient Request | proval by their | |
| Rx FASENRA® (benralizumab) What is your primary choice? ☐ FASENRA® (benralizumab) 30 mg/mL single-dose prefilled syringe Office-Administered (10-digit NDC: 0310-1730-30) ☐ FASENRA Pen™ (benralizumab) 30 mg/mL single-dose autoinjector Self-Administered (10-digit NDC: 0310-1830-30) ☐ Please send alcohol wipe and sterile gauze to patient Has this patient started therapy? ☐ Yes ☐ No If yes, how many doses has the patient received? ☐ Loading Dose 30 mg/mL solution in a single dose administered by subcutaneous injection once every 4 weeks for 3 doses | □ FASENRA® (benralizumab) 30 mg/m Office-Administered (10-digit NDC: □ FASENRA Pen™ (benralizumab) 30 m Self-Administered (10-digit NDC: 03 □ Please send alcoho □ Optional: Free Limited Free Limited Supply is available for elinsurance company for FASENRA. FASENRA® (benralizumab | nL single-dose pref 0310-1730-30) ng/mL single-dose 310-1830-30) I wipe and sterile g Supply (FLS) ligible patients who | illed syringe autoinjector jauze to patient Request o face a delay in app | | |
| Rx FASENRA® (benralizumab) What is your primary choice? ☐ FASENRA® (benralizumab) 30 mg/mL single-dose prefilled syringe Office-Administered (10-digit NDC: 0310-1730-30) ☐ FASENRA Pen™ (benralizumab) 30 mg/mL single-dose autoinjector Self-Administered (10-digit NDC: 0310-1830-30) ☐ Please send alcohol wipe and sterile gauze to patient Has this patient started therapy? ☐ Yes ☐ No If yes, how many doses has the patient received? ☐ Loading Dose 30 mg/mL solution in a single dose administered by subcutaneous injection once every 4 weeks for 3 doses Quantity:1 Refills: ☐ Maintenance Dose 30 mg/mL solution in a single dose administered by subcutaneous injection once every 8 weeks | □ FASENRA® (benralizumab) 30 mg/m Office-Administered (10-digit NDC: □ FASENRA Pen™ (benralizumab) 30 m Self-Administered (10-digit NDC: 03 □ Please send alcoho □ Optional: Free Limited Free Limited Supply is available for elinsurance company for FASENRA. FASENRA® (benralizumab) Quantity:1 Dose Instructions: | nL single-dose pref 0310-1730-30) ng/mL single-dose 310-1830-30) I wipe and sterile g Supply (FLS) ligible patients who | illed syringe autoinjector jauze to patient Request of face a delay in app | | |
| Rx FASENRA® (benralizumab) What is your primary choice? ☐ FASENRA® (benralizumab) 30 mg/mL single-dose prefilled syringe Office-Administered (10-digit NDC: 0310-1730-30) ☐ FASENRA Pen™ (benralizumab) 30 mg/mL single-dose autoinjector Self-Administered (10-digit NDC: 0310-1830-30) ☐ Please send alcohol wipe and sterile gauze to patient Has this patient started therapy? ☐ Yes ☐ No If yes, how many doses has the patient received? ☐ ☐ Loading Dose 30 mg/mL solution in a single dose administered by subcutaneous injection once every 4 weeks for 3 doses Quantity: ☐ ☐ Refills: ☐ ☐ Maintenance Dose 30 mg/mL solution in a single dose administered by subcutaneous injection once every 8 weeks Quantity: ☐ ☐ Refills: ☐ ☐ Refills: ☐ ☐ Refills: ☐ ☐ Refills: ☐ | □ FASENRA® (benralizumab) 30 mg/m Office-Administered (10-digit NDC: □ FASENRA Pen™ (benralizumab) 30 m Self-Administered (10-digit NDC: 03 □ Please send alcoho □ Optional: Free Limited Free Limited Supply is available for elinsurance company for FASENRA. FASENRA® (benralizumab) Quantity: _1 | nL single-dose pref 0310-1730-30) ng/mL single-dose 310-1830-30) I wipe and sterile g Supply (FLS) ligible patients who | illed syringe autoinjector jauze to patient Request of face a delay in app | | |
| Rx FASENRA® (benralizumab) What is your primary choice? ☐ FASENRA® (benralizumab) 30 mg/mL single-dose prefilled syringe Office-Administered (10-digit NDC: 0310-1730-30) ☐ FASENRA Pen™ (benralizumab) 30 mg/mL single-dose autoinjector Self-Administered (10-digit NDC: 0310-1830-30) ☐ Please send alcohol wipe and sterile gauze to patient Has this patient started therapy? ☐ Yes ☐ No If yes, how many doses has the patient received? ☐ Loading Dose 30 mg/mL solution in a single dose administered by subcutaneous injection once every 4 weeks for 3 doses Quantity:1 Refills: ☐ Maintenance Dose 30 mg/mL solution in a single dose administered by subcutaneous injection once every 8 weeks | □ FASENRA® (benralizumab) 30 mg/m Office-Administered (10-digit NDC: □ FASENRA Pen™ (benralizumab) 30 m Self-Administered (10-digit NDC: 03 □ Please send alcoho □ Optional: Free Limited Free Limited Supply is available for elinsurance company for FASENRA. FASENRA® (benralizumab) Quantity:1 Dose Instructions: | nL single-dose pref 0310-1730-30) ng/mL single-dose 310-1830-30) I wipe and sterile g Supply (FLS) ligible patients who | illed syringe autoinjector jauze to patient Request of face a delay in app | | |
| Rx FASENRA® (benralizumab) What is your primary choice? ☐ FASENRA® (benralizumab) 30 mg/mL single-dose prefilled syringe Office-Administered (10-digit NDC: 0310-1730-30) ☐ FASENRA Pen™ (benralizumab) 30 mg/mL single-dose autoinjector Self-Administered (10-digit NDC: 0310-1830-30) ☐ Please send alcohol wipe and sterile gauze to patient Has this patient started therapy? ☐ Yes ☐ No If yes, how many doses has the patient received? ☐ ☐ Loading Dose 30 mg/mL solution in a single dose administered by subcutaneous injection once every 4 weeks for 3 doses Quantity:1 Refills: Guantity:1 Refills: Known Allergies: | □ FASENRA® (benralizumab) 30 mg/m Office-Administered (10-digit NDC: □ FASENRA Pen™ (benralizumab) 30 m Self-Administered (10-digit NDC: 03 □ Please send alcoho □ Optional: Free Limited Free Limited Supply is available for elinsurance company for FASENRA. FASENRA® (benralizumab) Quantity:1 Dose Instructions: | nL single-dose pref 0310-1730-30) ng/mL single-dose 310-1830-30) I wipe and sterile g Supply (FLS) ligible patients who | illed syringe autoinjector jauze to patient Request of face a delay in app | | |
| Rx FASENRA® (benralizumab) What is your primary choice? ☐ FASENRA® (benralizumab) 30 mg/mL single-dose prefilled syringe Office-Administered (10-digit NDC: 0310-1730-30) ☐ FASENRA Pen™ (benralizumab) 30 mg/mL single-dose autoinjector Self-Administered (10-digit NDC: 0310-1830-30) ☐ Please send alcohol wipe and sterile gauze to patient Has this patient started therapy? ☐ Yes ☐ No If yes, how many doses has the patient received? ☐ ☐ Loading Dose 30 mg/mL solution in a single dose administered by subcutaneous injection once every 4 weeks for 3 doses Quantity: ☐ ☐ Refills: ☐ ☐ Maintenance Dose 30 mg/mL solution in a single dose administered by subcutaneous injection once every 8 weeks Quantity: ☐ ☐ Refills: ☐ Known Allergies: ☐ Refills: ☐ Last Injection Date: ☐ / / | □ FASENRA® (benralizumab) 30 mg/m Office-Administered (10-digit NDC: □ FASENRA Pen™ (benralizumab) 30 m Self-Administered (10-digit NDC: 03 □ Please send alcoho □ Optional: Free Limited Free Limited Supply is available for elinsurance company for FASENRA. FASENRA® (benralizumab) Quantity: 1 Dose Instructions: | nL single-dose pref 0310-1730-30) ng/mL single-dose 310-1830-30) I wipe and sterile g Supply (FLS) ligible patients who | illed syringe autoinjector jauze to patient Request o face a delay in apj | | |
| Rx FASENRA® (benralizumab) What is your primary choice? ☐ FASENRA® (benralizumab) 30 mg/mL single-dose prefilled syringe Office-Administered (10-digit NDC: 0310-1730-30) ☐ FASENRA Pen™ (benralizumab) 30 mg/mL single-dose autoinjector Self-Administered (10-digit NDC: 0310-1830-30) ☐ Please send alcohol wipe and sterile gauze to patient Has this patient started therapy? ☐ Yes ☐ No If yes, how many doses has the patient received? ☐ Loading Dose 30 mg/mL solution in a single dose administered by subcutaneous injection once every 4 weeks for 3 doses Quantity: ☐ ☐ Refills: ☐ ☐ Maintenance Dose 30 mg/mL solution in a single dose administered by subcutaneous injection once every 8 weeks Quantity: ☐ ☐ Refills: ☐ ☐ Refills: ☐ ☐ Refills: ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ | □ FASENRA® (benralizumab) 30 mg/m Office-Administered (10-digit NDC: □ FASENRA Pen™ (benralizumab) 30 m Self-Administered (10-digit NDC: 03 □ Please send alcoho □ Optional: Free Limited Free Limited Supply is available for endingurance company for FASENRA. FASENRA® (benralizumab) Quantity: 1 Dose Instructions: | nL single-dose pref 0310-1730-30) ng/mL single-dose 310-1830-30) I wipe and sterile g Supply (FLS) ligible patients who | autoinjector jauze to patient Request of face a delay in app | | |



Prescriber Authorization

I authorize Access 360 program to convey the attached prescription on my behalf to the pharmacy chosen above and to receive information on the status and related matters. By signing on Page 3, I certify that the medicine prescribed on this form is medically necessary based on my independent medical judgment, and I have received the necessary authorization to release the information included on this form and other Protected Health Information (as defined by HIPAA) to Access 360, the dispensing pharmacy, or other contractors for the purpose of seeking reimbursement or assisting in initiating or continuing therapy. Each practitioner is solely responsible for ensuring the accuracy of the information submitted.

I verify that the information provided on this form is accurate. I understand that the patient must have a diagnosis consistent with an FDA-approved indication for FASENRA to be eligible for free limited supply. I also understand I must submit a prescription compliant with my state law. Reimbursement for the cost of the product administered to the above patient on the date(s) indicated has not been sought and will not be sought from any source. Additionally, I understand that AstraZeneca reserves the right to conduct periodic audits of the records, excluding patientidentifiable data (unless patient authorization is on file with Access 360), of all entities receiving free limited supply. I understand that AstraZeneca reserves the right to modify or revoke this program at any time without notice. My signature confirms that this product was provided free of charge to this patient. (Using signature stamp or signing on behalf of the prescriber is not permitted).

Once completed and signed, fax this form to 1-833-329-2360. You may need to provide additional information depending on the type of support requested.



1-833-360-HELP (1-833-360-4357)



1-833-FAX-A360 (1-833-329-2360)



www.FasenraResources.com



Access360@AstraZeneca.com



One MedImmune Way, Gaithersburg, MD 20878

